丁螺环酮与阿普唑仑治疗广泛性焦虑对照研究

目的 比较丁螺环酮与阿普唑仑对广泛性焦虑的疗效。方法 将62例广泛性焦虑患者随机均分为两组,分别给予丁螺环酮和阿普唑仑治疗,疗程8周,用HAMA、TESS评定疗效与副反应。结果 疗程结束时,丁螺环酮组HAMA评分由入组时的26.58±4.72降为9.16±5.28,阿普唑仓组HAMA评分由25.36±7.85降为13.19±6.51,两组显著差异(P<0.05);丁螺环酮组TESS评分低于阿普唑仓组(P<0.05)。结论 丁螺环酮与阿普唑仑治疗广泛性焦虑都有效,且丁螺环酮疗效较好,副反应轻微。     

丁螺环酮与文拉法辛在广泛性焦虑症患者中的血药浓度及疗效的比较

目的探讨丁螺环酮与文拉法辛在广泛性焦虑症患者中的血药浓度及疗效对比。方法研究选取2013年6月~2016年6月期间在我院接受治疗的100例广泛性焦虑症患者作为对象。随机将患者分为丁螺环酮组、文拉法辛组。比较两组患者汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)及焦虑自评量表(SAS)评分,血药浓度与治疗效果间的关系,有效率及不良反应。结果两组患者经药物治疗后HAMA、HAMD及SAS评分均有下降(P0.05);文拉法辛组患者HAMA、HAMD及SAS评分均低于丁螺环酮组(P0.05)。两组患者治疗后精神性焦虑及躯体性焦虑评分较治疗前明显降低(P0.05);文拉法辛组患者治疗后精神性和躯体性焦虑评分均明显低于丁螺环酮组(P0.05)。两组患者的临床疗效和血药浓度均无明显相关性,且不良反应发生率无明显差异(P0.05)。结论文拉法辛与丁螺环酮治疗广泛性焦虑症均有较好的治疗效果,不良反应较低,但是文拉法辛抗焦虑治疗的效果优于丁螺环酮。     

丁螺环酮治疗精神分裂症患者病理性或药源性焦虑的临床效果

目的研究丁螺环酮治疗精神分裂症患者病理性或药源性焦虑的临床效果。方法选出2014年12月~2016年12月我院收入治疗的精神分裂症伴病理性或药源性焦虑患者110例开展调查研究,根据临床治疗方案不同分为治疗组与对照组(n=55),对照组单用抗精神病药物治疗,治疗组在对照组基础上加用丁螺环酮治疗,比较两组治疗后情况。结果治疗后治疗组BPRS评分焦虑忧郁、缺乏活力、思维障碍、激活性、敌对猜忌分值低于对照组,PANSS评分低于对照组(P0.05)。在治疗后第6与第8周,治疗组TESS评分显著低于对照组(P0.05)。从第二周开始,治疗组的HAMA评分减分快于对照组(P0.05)。治疗组治疗有效率(94.5%)显著高于对照组(76.4%)(P0.05)。结论丁螺环酮治疗精神分裂症能够迅速缓解患者精神病性症状,缓解焦虑情绪,安全性较高。     

乌灵胶囊辅助治疗对甲亢伴抑郁患者焦虑抑郁症状及睡眠质量的影响

目的探讨乌灵胶囊辅助治疗甲亢伴抑郁患者对焦虑抑郁症状及睡眠质量的影响。方法将96例甲亢伴抑郁患者随机分为观察组和对照组,每组48例,对照组采用甲巯基咪唑联合抗抑郁药西酞普兰治疗,观察组在对照组用药基础上联合应用乌灵胶囊辅助治疗,治疗8周后,比较两组汉密尔顿焦虑量表(HAMA)、汉密尔顿抑郁量表(HAMD)、匹兹堡睡眠指数(PSQI)等指标。结果观察组HAMA、HAMD评分均明显低于对照组(P0.05);睡眠质量、入睡时间、睡眠时间、睡眠效率、睡眠障碍、安眠药物、白天功能等评分均明显低于对照组(P0.05);观察组总有效率89.58%,明显优于对照组72.92%(P0.05)。结论乌灵胶囊辅助治疗有助于缓解甲亢伴抑郁症患者焦虑、抑郁症状,改善睡眠质量,提高临床疗效。     

丁螺环酮和阿普唑仑治疗广泛性焦虑研究

目的：比较国产丁螺环酮和阿普唑仑治疗广泛性焦虑的疗效和不良反应。方法：对78例广泛性焦虑按照就医顺序分为两组，分别服用丁螺环酮(38例)和阿普唑仑(40例)。疗程6周。于治疗前及治疗第1、2、4、6周末进行汉密尔顿焦虑量表(HAMA)及副反应量表(TESS)评定疗效和不良反应。结果：丁螺环酮和阿普唑仑的疗效相仿，丁螺环酮的不良反应少且轻微，无过度镇静和肌肉松弛作用，不产生药物依赖。结论：丁螺环酮是治疗广泛性焦虑较为理想的药物。     

文拉法辛缓释剂与丁螺环酮治疗广泛性焦虑障碍的对照研究

目的 评价文拉法辛缓释片与丁螺环酮治疗广泛性焦虑障碍的临床疗效和安全性.方法 58例广泛性焦虑障碍患者随机分为文拉法辛缓释片组（研究组）30例、丁螺环酮组（对照组）28例,共治疗8周.采用汉密尔顿焦虑量表（HAMA）、临床总体印象量表（CGI）评定临床疗效,不良事件量表（AE）评定安全性.结果 两组治疗后第1、2、4、6、8周末HAMA量表总分与治疗前比较均降低（P＜0.01）;两组的精神性焦虑因子和躯体性焦虑因子评分与治疗前评分比较均降低（P＜0.01）.研究组有效率83.3％,显效率66.7％;对照组有效率85.7％,显效率67.9％,两组比较差异无统计学意义（P＞0.05）.治疗后第1、2、4、6、8周末,两组CGI量表总分与治疗前比较均降低（P＜0.01）,两组药物不良反应的发生率比较差异无统计学意义（P＞0.05）,常见的不良反应有头痛、恶心、口干、头昏、失眠等.结论 文拉法辛缓释片与丁螺环酮片治疗广泛性焦虑障碍疗效确切,不良反应少而轻.     

认知行为疗法治疗原发性失眠的临床疗效及依从性分析

目的评价认知行为疗法治疗原发性失眠的临床疗效以及依从性的影响。方法选取2013-04—2015-11我院收治的原发性失眠患者52例为观察组,正常人52例为对照组,观察并比较2组PSQI(匹兹堡睡眠指数)、HAMA(汉密尔顿焦虑量表)、HAMD(汉密尔顿抑郁量表)等评分,观察组采取认知行为治疗,观察治疗效果。结果观察组PSQI、HAMA、HAMD等评分均明显高于对照组,差异有统计学意义(P0.05);观察组治疗结束后PSQI、HAMA以及HAMD等评分均明显降低,差异有统计学意义(P0.05);完成4次认知行为治疗的患者各项指标改善程度明显优于未完成者,差异有统计学意义(P0.05)。结论原发性失眠患者较正常人群睡眠指数较低,存在一定程度的焦虑与抑郁情绪,通过认知行为疗法,可明显改善其失眠症状,减轻焦虑与抑郁等不良心理,提高睡眠质量与睡眠效率,值得临床推广。     

右佐匹克隆联合睡眠集束化模式干预对高血压伴睡眠障碍患者心理弹性及认知功能的影响

目的 探究右佐匹克隆与睡眠集束化模式干预对高血压伴睡眠障碍患者的效果及对心理弹性、睡眠质量的影响。方法 选取我院2020年10月～2022年10月96例高血压伴睡眠障碍患者,根据抽签法分组。两组均给予常规降压治疗,对照组给予睡眠集束化模式干预,观察组48例增加右佐匹克隆治疗,对比两组血压：舒张压、收缩压水平;睡眠质量：匹兹堡睡眠质量指数（Pittsburgh Sleep Quality Index,PSQI）评分;心理弹性：汉密尔顿焦虑量表（Hamilton Anxiety Scale,HAMA）、汉密尔顿抑郁量表（Hamilton Depression Scale,HAMD）;认知功能：简易精神状况检查表（Brief Psychiatric Status Checklist,MMSE）、病理行为评分表（Pathological Behavior Scale,BEHA VE-AD）及不良反应。结果 治疗后两组患者MMSE、BEHA VE-AD评分、舒张压、收缩压水平、不良反应发生率差异均无统计学意义（P>0.05）;治疗后观察组PSQI、HAMA、HAMD评分低于对照组,有统计学...     

黛力新联合右佐匹克隆治疗伴抑郁和(或)焦虑及失眠症状神经紧张头痛的疗效观察

目的探讨黛力新联合右佐匹克隆治疗合并抑郁和(或)焦虑状态及失眠症状的慢性紧张型头痛的临床效果。方法选取我院2014-06—2015-06收治的伴抑郁和(或)焦虑状态及失眠症状的慢性紧张型头痛患者208例为研究对象,按照治疗方式分为2组,对照组100例使用氟哌噻吨美利曲辛,观察组108例基于对照组加用右佐匹克隆,对比2组临床效果。结果 2组治疗前PSQI、HAMA、HAMD比较差异无统计学意义(P0.05),治疗后观察组PSQI评分显著优于对照组(P0.05,t=6.381),2组组内治疗前后PSQI、HAMA、HAMD比较差异均有统计学意义(P0.05);2组治疗前后TESS比较差异无统计学意义(P0.05)。结论对抑郁和(或)焦虑状态及失眠症状的慢性紧张型头痛患者采用氟哌噻吨美利曲辛联合右佐匹克隆治疗疗效显著,可减少不良反应,安全可靠,有临床推广价值。     

坦度螺酮治疗广泛性焦虑对照观察

目的：评价新药坦度螺酮治疗广泛性焦虑的有效性和安全性。方法：采用双盲双模拟方法。47例患者分别口服坦度螺酮30～60mg／d或丁螺环酮15～30mg／d。疗程6周，减药观察2周。结果：两组汉密尔顿焦虑量表(HAMA)评分在治疗结束时较基线显著减少(P＜0．01)。有效率坦度螺酮组79．2％，丁螺环酮组87．0％，差异无显著性。两组常见不良反应有口干、便秘、恶心。结论：坦度螺酮与丁螺环酮具有类似的疗效和不良反应，为治疗广泛性焦虑安全而有效的新药。     

Satisfaction with quality of life varies with temperament types of patients with schizophrenia

We sought to explore the relationships of three temperament factors with domain-specific subjective quality of life (QOL) of patients with schizophrenia. Ninety patients with schizophrenia were evaluated using the Quality of Life Enjoyment and Life Satisfaction Questionnaire, the Tridimensional Personality Questionnaire, the Positive and Negative Syndromes Scale, the Distress Scale for Adverse Symptoms, the Insight and Treatment Attitudes Questionnaire, the Insight Self-Report Scale, and standardized questionnaires for self-reported emotional distress and stress process-related variables. Predictors of domain-specific QOL were identified using multiple regression techniques. Temperament factors explain 6% to 16% of variability in QOL domain scores among patients with schizophrenia after controlling for the remaining variables (emotional distress, social support, self-esteem, avoidance coping, age, side effects, and depression). We found that higher levels of novelty seeking are associated with better general QOL, physical health, and more positive subjective feelings, whereas higher levels of reward dependence are related to better satisfaction from social relationships. Higher levels of harm avoidance are associated with poorer satisfaction with general activities, and medication. Thus, temperament factors, as assessed by the Tridimensional Personality Questionnaire, substantially influence satisfaction with life quality in schizophrenia. Novelty seeking, reward dependence, and harm avoidance are associated with different domains of QOL.     

Compliance with health regimens of adolescents with epilepsy

The purpose of this paper was to describe the compliance of adolescents with epilepsy and some factors connected to it. Altogether 300 individuals with epilepsy aged 13-17 years were randomly selected from the Finnish Social Insurance Institution's register. Every fifth person on the list was included in the sample. Seventy-seven per cent (n= 232) of the selected adolescents with epilepsy returned a questionnaire sent to them relating to compliance. The data were analysed using the SPSS software. Twenty-two per cent of the adolescents with epilepsy felt that they complied fully with their suggested health regimens, while 44% placed themselves in the category of "satisfactory compliance", and the remaining 34% reported poor compliance. Compliance with their recommended life-style was poorest, while the highest degree of compliance was recorded for medication. Background variables, such as the duration of the disease, exercise, smoking, alcohol-intake and the number of seizures, were statistically significantly related to compliance (P< 0.001). Good motivation, a strong sense of normality, experience of results, subjective outcome, energy and will-power, support from parents, physicians and nurses, and a positive attitude towards to the disease and its treatment, no threat to social and emotional well-being and no fears of complications and no fear of seizures explained good compliance (P< 0.001).     

Treatment of patients with tardive dystonia with olanzapine

Tardive dystonia represents a complication of long-term use of neuroleptics and its treatment is often unsatisfactory. Atypical neuroleptics appear to improve tardive dystonia, and cases of tardive dystonia successfully managed with clozapine have been reported. The aim of this open-label video-blinded study was to evaluate the antidystonic efficacy of olanzapine, a new atypical neuroleptic with a low risk of agranulocytosis, in a group of four patients (one man and three women) with tardive cervical dystonia. They developed severe dystonia after several years of neuroleptic treatment. Extensive laboratory evaluations, as well as neurophysiologic and neuroradiologic investigations, were negative. Olanzapine was started at a dose of 5 mg/d and increased up to 7.5 mg/d. All patients were evaluated at baseline and after 2, 4, 8, and 12 weeks of treatment, using the Toronto Western Spasmodic Torticollis Rating Scale, and videotaped. At the end of the trial, the videotapes were reviewed and scored by a blind observer. A self-rating visual analog scale completed the disability evaluation.A moderate to marked improvement in dystonia was observed in all patients, and significant differences were observed in Toronto Western Spasmodic Torticollis Rating Scale scores and videotape ratings after 8 and 12 weeks of treatment compared with the basal values (p < 0.05). The average percentage of improvement in Toronto Western Spasmodic Torticollis Rating Scale score and visual analog scale was 26.4% and 42.6%, respectively. No serious side effects were reported at the maximum dosage reached (7.5 mg/d). This study warrants a larger controlled study to conclusively demonstrate the efficacy of olanzapine in tardive dystonia.     

血管内栓塞治疗未破裂脑动静脉畸形并发癫痫患者的预后分析

目的分析血管内栓塞治疗未破裂脑动静脉畸形(CAVM)并发癫痫患者的预后情况。方法选择2013年3月至2017年6月收治的符合诊断标准的CAVM并发癫痫发作患者49例为研究对象,分析血管内栓塞治疗后患者的临床症状、生活质量(QOLIE-31)改善情况。结果患者经血管内栓塞治疗后,QOLIE-31各项指标(除了药物影响)评分均明显提高,高于治疗前(P0.05);Spetzler-Martin分级与Engel分级的I~II级例数多于治疗前(P0.05),同时Spetzler-Martin分级I~II级生活质量评分(76.04±18.33)分明显高于III~V级的(65.65±16.76)分(P0.05);Engel分级I~II级的生活质量评分(75.25±17.78)分明显高于III~V级的(66.23±13.22)分(P0.05);血管内栓塞比例80%的生活质量总评分(78.37±18.87)分明显高于栓塞比例80%的(64.16±16.92)分(P0.05);术后患者的头疼症状中重度例数明显低于治疗前(P0.01);患者的NIHSS评分和MRS评分均明显低于治疗前,头疼症状的生活质量评分高于治疗前(均P0.05)。结论血管内栓塞能明显改善未破裂脑动静脉畸形并发癫痫患者的头疼症状、癫痫发作情况、神经功能缺损,提高血管内栓塞比例能够提高患者生活质量。